(Total Views: 264)
Posted On: 12/19/2018 11:08:06 AM
Post# of 72436
Gotcha. It seems clear from the last press release that the company is utterly focused on Bril-OM and partnerships now. When there is partnership money, they can get Kevetrin stuff going again. I'm glad that they are focused on the Bril-OM pathway towards approval. Having a drug complete Phase 3 will make a huge difference -- especially when we know it's practically a slam-dunk, given the great results from the earlier clinical trials.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)